Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Optizum Study: A Randomized, Blinded Single Center Study Evaluating the Optilume BPH Catheter System and the Rezum Water Vapor Therapy for the Treatment of Benign Prostatic Hyperplasia

NCT06769997 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT06769997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06769997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Optizum Study: A Randomized, Blinded Single Center Study Evaluating the Optilume BPH Catheter System and the Rezum Water Vapor Therapy for the Treatment of Benign Prostatic Hyperplasia
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Not applicable
Overall status
Recruiting
Start date
May 9, 2025
Completion date
January 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia (bph), lower urinary track symptoms